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Abstract
Background: Systemic lupus erythematosus (SLE) is a multi-system, complex disease in which the environment
interacts with inherited genes to produce broad phenotypes with inter-individual variability. Of 46 single nucleotide
polymorphisms (SNPs) shown to confer genetic risk for SLE in recent genome-wide association studies, 30 lie within
noncoding regions of the human genome. We therefore sought to identify and describe the functional elements
(aside from genes) located within these regions of interest.
Methods: We used chromatin immunoprecipitation followed by sequencing to identify epigenetic marks
associated with enhancer function in adult neutrophils to determine whether enhancer-associated histone marks
were enriched within the linkage disequilibrium (LD) blocks encompassing the 46 SNPs of interest. We also
interrogated available data in Roadmap Epigenomics for CD4+ T cells and CD19+ B cells to identify these same
elements in lymphoid cells.
Results: All three cell types demonstrated enrichment of enhancer-associated histone marks compared with
genomic background within LD blocks encoded by SLE-associated SNPs. In addition, within the promoter regions
of these LD blocks, all three cell types demonstrated enrichment for transcription factor binding sites above
genomic background. In CD19+ B cells, all but one of the LD blocks of interest were also enriched for
enhancer-associated histone marks.
Conclusions: Much of the genetic risk for SLE lies within or near genomic regions of disease-relevant cells that are
enriched for epigenetic marks associated with enhancer function. Elucidating the specific roles of these noncoding
elements within these cell-type-specific genomes will be crucial to our understanding of SLE pathogenesis.
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Background
Systemic lupus erythematosus (SLE) is a complex trait
believed to be caused by gene–environment interactions
that lead to a perturbed immunologic state in which
autoantibodies, immune complex deposition, and com-
plement activation contribute to systemic inflammation
and target tissue damage. The genetics of systemic lupus
has been studied extensively, in particular its association
with complement deficiencies. Although rare, C1q defi-
ciency is the strongest genetic risk factor for SLE [1, 2].
C1r and C1s deficiencies are commonly inherited
together, and over 50% of these patients develop SLE [3].
Moreover, homozygous C2 and C4 deficiencies have
been shown to predispose toward SLE [4–6].
Other than complement deficiencies, however, associa-
tions between SLE and functions of specific genes have
been harder to clarify. This situation became even more
confusing as data began to emerge from genome-wide
association studies (GWAS) and genetic fine mapping
studies [7–9], where the majority of risk-associated
single nucleotide polymorphisms (SNPs) occurred in
noncoding regions of the genome, often considerable
distances (in genomic terms) from protein-coding genes
and their promoters. Thus, while it is still common in
the literature to identify disease-associated SNPs by their
nearest gene, most genetic risk for SLE does not appear
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to be within “genes,” as conventionally understood, at
all. In this respect, SLE resembles almost every other
complex trait studied by GWAS [10]. Maurano et al.
[10] have shown that most SNPs for most complex traits
lie within genomic regions identified by projects like EN-
CODE, Roadmap Epigenomics, and Blueprint Epige-
nomics as regulatory regions, often regions active during
fetal life. This observation has been confirmed from
studies of specific diseases. Recently, for example, Jiang
et al. [11] demonstrated that regions of genetic risk for
juvenile idiopathic arthritis (JIA) identified by genetic
fine mapping using Illumina Immunochip arrays are
enriched for H3K4me1 and or H3K27ac histone marks,
epigenetic signatures associated with enhancer function.
There is thus a broadly emerging consensus in the fields
of genetics and functional genomics that genetic risk for
complex traits likely involves specific aspects of tran-
scriptional regulation and coordination rather than aber-
rant function of protein-coding genes.
In the current study, we examined the “epigenetic
landscape” around known SLE-associated SNPs in an ef-
fort to better understand the potential significance of
disease-associated SNPs. We focused on three cell types
known to contribute to SLE pathogenesis: CD19+ B
cells, CD4+ T cells, and neutrophils [12–16]. We used
ENCODE and Roadmap Epigenomics data as well as
data generated in our own laboratory (for neutrophils)
to identify functional elements within these regions.
Methods
We queried the chromatin landscape around SNPs whose
associations with SLE are well documented [17]. In
addition, we queried recently reported SNPs found in a
large Asian population [18]. CD19+ B-cell and CD4+ T-cell
data were queried from ENCODE, while neutrophil RNA
sequencing (RNAseq) and chromatin immunoprecipitation
sequencing (ChIP-seq) data for H3K4me1/H3K27ac data
were generated in our laboratory and have been reported
recently [11]. Laboratory methods for ChIP-seq and RNA-
seq data are described briefly in the following.
Healthy adults
Enhancers are both cell specific and cell-state specific
[19]. Because neutrophils were not among the cells stud-
ied in either the ENCODE or Roadmap Epigenomics
projects, we sought to create a genomic map for enhancer
element locations using normal adult neutrophils. We ob-
tained neutrophils from three healthy adults aged 25–40
using techniques we have described previously [11].
Chromatin immunoprecipitation for histone marks
H3K4me1 and H3K27ac and sequencing
Neutrophils were isolated as described previously [20].
The ChIP assay was carried out according to the
protocol of the manufacturer (Cell Signaling Technolo-
gies Inc., Danvers, MA, USA) and has been described in
our work published previously [11]. Briefly, adult neutro-
phils were incubated with newly prepared 1% formalde-
hyde in PBS at room temperature (RT). Crosslinking
was quenched by adding 1× glycine. The crosslinked
samples were centrifuged, the supernatant discarded,
and the pellet washed with cold PBS followed by resus-
pension in 10 ml ice-cold Buffer A plus DTT, PMSF, and
protease inhibitor cocktail. Cells were incubated on ice
and then centrifuged at 4 °C to precipitate nucleus pel-
lets, which were then resuspended in 10 ml ice-cold Buf-
fer A plus DTT. The nucleus pellet was incubated with
Micrococcal nuclease for 20 minutes at 37 °C with fre-
quent mixing to digest DNA. Sonication of nuclear ly-
sates was performed using a Sonic Dismembrator (FB-
705; Fisher Scientific, Pittsburgh, PA, USA) on ice. After
centrifugation of sonicated lysates, the supernatant was
transferred into a fresh tube. Fifty microliters of the
supernatant (chromatin preparation) was taken to
analyze chromatin digestion and concentration. Fifteen
micrograms of chromatin was added into 1× ChIP buffer
plus protease inhibitor cocktail to a total volume of
500 μl. After removal of 2% of chromatin as the input
sample, the antibodies were added to the ChIP buffer.
The antibodies against respective histone modifications
were rabbit polyclonal antibodies against histone H3
acetylated at lysine 27 (H3K27ac) and histone H3 mono-
methylated at lysine 4 (H3K4me1) from Cell Signaling
Technologies. The negative control was normal IgG
(Cell Signaling Technologies). After immunoprecipita-
tion, the magnetic beads were added and incubated for
another 2 hours at 4 °C. The magnetic beads are cova-
lently coupled to a truncated form of recombinant pro-
tein G. They were then collected with a magnetic
separator (Life Technologies, Grand Island, NY, USA).
The beads were washed sequentially with low and high
salt wash buffer, followed by incubation with elution buf-
fer to elute protein/DNA complexes and reverse cross-
links of protein/DNA complexes to release DNA. The
DNA fragments were purified by spin columns and dis-
solved in the elution buffer. The crosslinks of input sam-
ple were also reversed in elution buffer containing
proteinase K before purification with spin columns. DNA
sequencing was then conducted using the Illumina HiSeq
2500 at the next-generation sequencing center in Univer-
sity at Buffalo.
ChIP-seq analysis of neutrophils
Analysis of the ChIP-seq data was carried out exactly as
described previously [11]. MACS2 v2.1.10 [21] was
applied for calling regions enriched with histone marks
against the input sample, with the parameters “–
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nomodel –extsize 150 –broad –broad-cutoff 0.1”. Details
of these analyses are further described by Jiang et al.
[11].
CD19+ B-cell and CD4+ T-cell analysis
In order to compare data from neutrophils with existing
data from CD19+ B cells and CD4+ T cells, we queried
data generated from the Roadmap Epigenomics Project
[22]. Raw ChIP-seq data for CD19+ primary cells were
downloaded from the GEO database [23]
[GEO:GSM1027296, GEO:GSM1027287, GEO:GSM102
7300, GEO:GSM1027304] for H3K4me1, H3K27ac,
H3K4me3, and input control respectively. Raw ChIP-seq
data for CD4+ T cells were downloaded [GEO:GSM12
20567, GEO:GSM1220560, GEO:GSM1102798, GEO:
GSM1102805] for H3K4me1, H3K27ac, H3K4me3, and
input control respectively. The methods for mapping
and region-calling are the same as those was used to
analyze neutrophil data.
ENCODE transcription factor binding site enrichment
ENCODE transcription factor binding site (TFBS)
data were downloaded from UCSC Genome Browser
ENCODE (http://hgdownload.cse.ucsc.edu/golden-
Path/hg19/encodeDCC/wgEncodeRegTfbsClustered/).
Only the TFBS information derived from blood cells
was used for analysis. The whole genome was binned
to 100 bp bins and intersected with H3K27ac,
H3K4me1, or H3K4me3 peak regions, which were
used as background. Fisher’s exact test was applied
to test the significance of enrichment for TFBS for
each transcription factor (TF) within H3K27ac,
H3K4me1, or H3K4me3 peaks within linkage dis-
equilibrium (LD) blocks compared with peak regions
in the whole genome. The cutoff point for the false
discovery rate (FDR) was set to 0.05.
Results
Association of regions of genetic risk with functional
elements within neutrophil genomes
We searched the LD regions near (within 5 kb of ) each
GWAS index locus for association with histone marks
from ChIP-seq. LD blocks were defined for 46 out of
the 58 SNPs described in recent GWAS [17, 18] using
information from the SNAP database (http://www.broa-
dinstitute.org/mpg/snap) [24] by querying data from
the 1000 Genomes Project pilot and the HapMap3
database. LD blocks were defined using r2 < 0.9.
We further investigated H3K4me1, H3K4me3, and
H3K27ac distal regions relative to transcription start
sites. The distal regions typically correspond to cis-act-
ing enhancers located far away from the gene(s) they
regulate [25]. Regions containing at least one methyl-
ated (H3K4me1 or H3K4me3) and one acetylated
histone mark (H3K27ac) were referred to as active en-
hancers, and those that contained only one methylated
histone group or H3K27ac region were referred to as
poised enhancers or H3K27ac-active enhancers, re-
spectively. Of note, H3K4me3 appears to be cell-type
specific, expressed in cells of the lymphoid lineage, and
noted to be an important histone mark for enhancer
activity [26].
We found functional elements within 5 kb of 36 of the
46 SNPs in adult neutrophils. Epigenetic evidence for ac-
tive enhancers were found in 29 LD blocks, poised en-
hancers in six LD blocks, and H3K27ac-active enhancers
in one LD block (Table 1). Using Fisher’s exact test,
these regions were significantly enriched for enhancer
activity above the genomic background (p < 0.05)
(Fig. 1).
Enhancer elements within CD4+ T and CD19+ B cells
Using the same approaches as we used for neutro-
phils, we interrogated available H3K4me1, H3K4me3,
and H3K27ac ChIP-seq data from the Roadmap Epi-
genomics project for CD4+ T and CD19+ B cells. We
found considerable overlap for the locations of
H3K4me1 and H3K27ac peaks between our neutro-
phil data and resting CD4+ T cells. Functional ele-
ments were found within 39 of the 46 SNPs of
interest in CD4+ T cells. Epigenetic evidence for ac-
tive enhancers was found in 30 LD blocks, and for
poised enhancers in nine LD blocks; no LD blocks
contained H3K27ac marks alone (Table 2).
In CD19+ B cells, we identified functional elements
found in 42 of 46 SNPs of interest. Epigenetic evi-
dence for active enhancers was present in 32 LD
blocks, and for poised enhancers in 10 LD blocks; no
LD blocks contained H3K27ac histone marks alone
(Table 3). There are thus more SNPs of interest in
SLE with functional elements within lupus-associated
LD blocks in CD19+ cells than in either CD4+ cells
or neutrophils (p < 0.05). Representative screenshots
from the UCSC Genome Browser with two of the LD
blocks of interest are shown in Fig. 2.
While it is difficult at this time to determine exact
differences in the acetylation and methylation of pa-
tients with SLE compared with healthy controls due
to the scarcity of available data, we did perform an
analysis of differentially methylated regions as identi-
fied by Absher et al. [27] in adult SLE patients. This
analysis revealed only one gene (PBX2, on chromo-
some 6) lying within the same LD block as rs1270942
to be aberrantly methylated in T cells, B cells, and/or
monocytes in SLE patients. In addition, analysis of
differentially methylated regions identified by Coit
et al. [28] in the neutrophils of adult SLE patients
compared with healthy adult data from our laboratory
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and available in Roadmap Epigenomics revealed that
none of these regions were located within the LD
blocks containing the SLE-associated SNPs. Less than
40% of these regions contained enhancer marks in
healthy adult neutrophils. Fewer than 1/3 of these
regions contained enhancer marks in healthy adult
CD4+ and CD19+ cells.
Transcription factor binding sites at enhancer regions in
LD blocks in CD4+ cells, CD19+ cells, and neutrophils
We next sought to further test the likely functional
significance of H3K4me1, H3K4me3, and H3K27ac
enrichment within the SLE-associated LD blocks. We
therefore analyzed the TF ChIP-seq data from blood
cells obtained from the UCSC Genome Browser EN-
CODE data portal [29] to determine whether there
was significant enrichment for TF binding within the
enhancer regions located within SLE-associated LD
blocks compared with other regions (Fig. 3). We
investigated both promoter and nonpromoter regions
within the regions where histone marks (H3K4me1,
H3K4me3, and H3K27ac) are associated with enhan-
cer activities. As expected, promoter regions within
these LD blocks (defined as (−5 K, 1 K) of transcrip-
tion start sites) are highly enriched for TF binding
sites. Furthermore, we identified more enrichment for
TF binding sites in H3K4me3 peak regions than in ei-
ther H3K27ac or H3K4me1 peak regions in promoter
sites in CD19+ and CD4+ T cells (p < 0.05). Overall,
the LD blocks containing lupus-associated SNPs
appeared to be in active, dynamic regions of leukocyte
genomes as determined by the abundance of tran-
scription factor binding motifs within these regions
Of note, 23 out of 46 SNP regions have shared histone
modifications in all three cell types investigated. There
are 102 genes located within the 46 SNP LD blocks,
which are involved in 26 Panther pathways, including
T-cell and B-cell activation, and Jak/STAT signaling
pathways (Additional file 1: Table S1). Moreover, Farh
et al. [30] demonstrated that many causal variants which
map to immune-cell enhancers may gain histone acetyl-
ation and transcribe enhancer-associated RNA upon im-
mune stimulation. This could indicate that the majority
















rs10028805 4 102736456–102762581 0 0 No
rs10036748 5 150457485–150461049 55 388 Yes
rs10488631 7 128585616–128711874 104 468 Yes
rs1059312 12 129277164–129288534 44 84 Yes
rs10774625 12 111884608–112007756 178 368 Yes
rs10807150 6 35154315–35278796 160 263 Yes
rs10936599 3 169477506–169528523 41 58 Yes
rs11644034 16 85967285–85980534 0 24 Yes
rs11889341 2 191943742–191970120 0 0 No
rs12022418 1 192521591–192535107 17 45 Yes
rs1270942 6 31704294–32175415 126 0 Yes
rs12802200 11 566936–567627 0 39 Yes
rs1610555 18 67523453–67544046 0 0 No
rs1801274 1 161470042–161479745 36 317 Yes
rs1885889 13 100084234–100104106 25 53 Yes
rs2009453 11 65399528–65405300 78 237 Yes
rs223881 16 57386566–57317134 0 0 No
rs2286672 17 4706123–4712617 0 3 Yes
rs2289583 15 75285114–75370012 227 386 Yes
rs2305772 19 52021247–52034940 0 0 No
rs2421184 5 158884119–158886939 0 0 No
rs2431697 5 159879978–159883217 0 0 No
rs2476601 1 114303808–114377568 113 297 Yes
rs2663052 10 50045456–50081232 0 0 No
rs2732549 11 35073852–35098193 26 106 Yes
rs2736340 8 11337587–11353000 0 0 No
rs2941509 17 37885383–38077485 308 693 Yes
rs3024505 1 206939904–206943968 0 66 Yes
rs34572943 16 31272353–31276811 79 150 Yes
rs3768792 2 213871709–213890232 0 0 No
rs3794060 11 71138710–71203790 62 125 Yes
rs4917014 7 50278187–50308811 66 65 Yes
rs4948496 10 63803472–63819903 67 83 Yes
rs61616683 22 39747050–39756650 0 22 Yes
rs6568431 6 106574794–106597639 15 15 Yes
rs6740462 2 65654364–65667272 26 35 Yes
rs6932056 6 138132123–138243700 175 286 Yes
rs740840 12 6327008–63600683 38 86 Yes
rs7444 22 21920817–21983260 153 420 Yes
rs7556469 1 198607998–198637582 379 487 Yes
rs7726414 5 133232663–13877357 252 1090 Yes
rs7941765 11 128499000–128500215 59 99 Yes
rs849142 7 28162674–28200097 17 222 Yes
Table 1 Histone marks in the SNP linkage disequilibrium blocks
in neutrophils (Continued)
rs9462027 6 34563164–34828553 167 717 Yes
rs9652601 16 11164567–11207894 63 105 Yes
rs9782955 1 235907825–236041129 322 511 Yes
Linkage disequilibrium blocks were obtained from the 1000 Genomes Project
pilot 1 and/or HapMap3 database
Chr chromosome, GWAS genome-wide association studies, SNP single
nucleotide polymorphism
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of SNPs are functional SNPs. However, expression quan-
titative loci analysis (eQTL) revealed that only one SNP
(rs2736340) was associated with a target gene
(FAM167A). Similarly, when the SNPs of interest were
compared with genes identified by Bennett et al [31].
whose expression was upregulated in SLE patients, only
one gene was found to lie in the same LD block as one
of the identified SNPs: a phorbolin-1 like gene from the
interferon family lies in the same LD block as SNP
rs61616683.
Discussion
Multiple GWAS in human disease have yielded surpris-
ing data demonstrating that a significant majority of
disease-associated polymorphisms are located within
noncoding regions of the genome [8, 9], i.e., those re-
gions of the genome where transcription is coordinated
on a genome-wide basis [32]. In fact, only 1–2% of the
human genome is believed to span protein-coding genes
[33, 34] and the remaining DNA is believed to incorpor-
ate an abundance of regulatory elements that contribute
to maintenance of a cell’s identity and/or regulate spe-
cific cell functions.
Results of recent GWAS in SLE also illustrate this
point. Of 46 SNPs identified by Bentham et al. and Sun
et al. [17, 18] as conferring risk for SLE, only 16 lie
within coding regions. In this study, we demonstrate that
these SLE-associated SNPs lie within LD blocks contain-
ing histone marks commonly associated with enhancer
function. We identified these marks in three cell types
known to contribute to SLE pathogenesis and/or disease
manifestations: CD4+ T cells, CD19+ B cells, and
neutrophils.
Enhancers are cis-acting, active regions of DNA
that promote gene transcription. Enhancers act by
binding transcription factors and other transcriptional
regulators that then alter the three-dimensional con-
formation of chromatin and facilitate the interaction
between gene promoters and protein–DNA com-
plexes. Enhancers may lie considerable distances from
the promoters they regulate and may not regulate the
genes closest to them [35]. Enhancers may also be
cell-type specific and tissue specific, and may regulate
more than one gene [19, 36]. For example, Martin et
al. [35] recently used HiC chromosome capture ap-
proaches to identify long-range interactions between
autoimmune disease risk loci and target genes. They
demonstrated that SNPs lying large distances apart
(in genomic terms) might either interact with the
nearest gene or bypass multiple genes lying nearer to
them to interact with those situated more distally.
The finding that the genetic risk for SLE lies largely
within functional, noncoding regions of the human
genome that contain regulatory elements in neutro-
phils, CD4+ T cells, and CD19+ B cells invites a new
perspective in disease pathogenesis. All three cell
types have been implicated in the pathogenesis of
SLE [12–16]. Preliminary studies in adult SLE used
RNAseq and found differentially expressed genes
comprising different cellular functions from distinct
leukocyte populations (in particular, from B cells and
monocytes) [37]. Thus, cell-type-specific differences in
gene expression may contribute to the pathogenesis
of SLE. Similar findings of risk in the noncoding gen-
ome have been observed in the neutrophils and CD4+
T cells of JIA patients [11].
Our results demonstrate that, particularly in lympho-
cytes, there is copious transcription factor binding in
H3K4me1/H3K4me3/H327ac-marked regulatory regions
encompassed by the LD blocks containing SLE-
associated SNPs, providing further evidence that these









































Fig. 1 Number of H3K27ac, H3K4me1, and H3K4me3 peak regions (histone marks) in linkage disequilibrium blocks. a Box plot of the raw number
of H3K27ac regions in CD4+ cells, CD19+ cells, and neutrophils. b Box plot of the raw number of H3K4me1 regions in CD4+ cells, CD19+ cells, and
neutrophils. c Box plot of the raw number of H3K4me3 regions in CD4+ and CD19+ cells
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rs10028805 4 102736456–102762581 0 0 0 No
rs10036748 5 150457485–150461049 18 35 22 Yes
rs10488631 7 128585616–128711874 11 30 14 Yes
rs1059312 12 129277164–129288534 2 19 0 Yes
rs10774625 12 111884608–112007756 2 15 0 Yes
rs10807150 6 35154315–35278796 89 116 53 Yes
rs10936599 3 169477506–169528523 30 22 36 Yes
rs11644034 16 85967285–85980534 13 31 6 Yes
rs11889341 2 191943742–191970120 0 9 0 Yes
rs12022418 1 192521591–192535107 0 0 0 No
rs1270942 6 31704294–32175415 29 69 228 Yes
rs12802200 11 566936–567627 0 0 0 No
rs1610555 18 67523453–67544046 0 1 0 Yes
rs1801274 1 161470042–161479745 0 0 6 Yes
rs1885889 13 100084234–100104106 20 38 10 Yes
rs2009453 11 65399528–65405300 5 17 3 Yes
rs223881 16 57386566–57317134 0 0 0 No
rs2286672 17 4706123–4712617 0 7 7 Yes
rs2289583 15 75285114–75370012 4 66 14 Yes
rs2305772 19 52021247–52034940 0 0 0 No
rs2421184 5 158884119–158886939 0 3 0 Yes
rs2431697 5 159879978–159883217 0 0 0 No
rs2476601 1 114303808–114377568 65 53 25 Yes
rs2663052 10 50045456–50081232 0 0 0 No
rs2732549 11 35073852–35098193 23 47 0 Yes
rs2736340 8 11337587–11353000 0 2 11 Yes
rs2941509 17 37885383–38077485 228 342 116 Yes
rs3024505 1 206939904–206943968 1 47 0 Yes
rs34572943 16 31272353–31276811 0 11 0 Yes
rs3768792 2 213871709–213890232 0 0 2 Yes
rs3794060 11 71138710–71203790 14 29 28 Yes
rs4917014 7 50278187–50308811 59 59 5 Yes
rs4948496 10 63803472–63819903 41 53 27 Yes
rs61616683 22 39747050–39756650 0 0 0 No
rs6568431 6 106574794–106597639 4 34 0 Yes
rs6740462 2 65654364–65667272 0 28 28 Yes
rs6932056 6 138132123–138243700 97 117 53 Yes
rs740840 12 6327008–63600683 1 25 0 Yes
rs7444 22 21920817–21983260 5 133 13 Yes
rs7556469 1 198607998–198637582 166 41 126 Yes
Hui-Yuen et al. Arthritis Research & Therapy  (2016) 18:281 Page 6 of 12
shown that both promoters and enhancers exhibit sig-
nificant changes in monocytes from SLE patients when
compared with healthy controls. In particular, differen-
tially methylated regions in SLE were significantly
enriched in potential interferon-related TFBS. Further-
more, the importance of histone modifications (e.g.,
epigenetic marks) in regulating transcription is demon-
strated in the recent work of Zhang et al. These authors
identified distinct patterns of H3K4me3 methylation
associated with aberrations in gene expression in
monocytes from patients with SLE [39]. Their results
demonstrated that genes overexpressed in SLE tended to
respond to H3K4me3 changes downstream of transcrip-
tion start sites.
Our findings, as well the expanded understanding of
gene regulation that has emerged in the past 10 years, sug-
gest a new paradigm of SLE pathogenesis that includes
complex interactions between the innate and adaptive
immune systems that may emerge because of disordered
transcriptional regulation in both lymphoid and myeloid
cells. The field of functional genomics is demonstrating
that transcription is a complex process that must be regu-
lated and coordinated on a genome-wide basis to maintain
normal cellular function [32]. For example, transcription
factors do not simply bind to DNA independently from
other proteins, but rather interact with one another in
layers of complexity. This newer finding suggests that
transcriptional and regulatory networks are created for
complex biological processes, and that even small pertur-
bations of this system (e.g., from genetic variance or
environmentally-induced epigenetic alterations) could
accumulate over time. These cumulative small perturba-
tions result in significant disorders in the regulation and
coordination of transcription, ultimately leading to the
development of disease. These newer data suggest that
complex disorders may be due less to “bad genes” than to
faulty gene regulation [40, 41]. Perhaps SLE, and many of
the other conditions we refer to as “autoimmune
diseases,” may be better understood as a disease of disor-
dered transcription.
It is important to keep in mind the limitations of
our study. First, both Bentham et al. and Sun et al.
[17, 18] focused on regions of immunologic interest
when performing GWAS, in that both groups used
the Illumina Immunochip. The GWAS thus identified
only selected genomic regions of specific immunologic
interest that confer risk for SLE. It will be important
to investigate whether additional risk loci would be
revealed with a broadening of the query to genes that
regulate chromatin access, or genes that regulate
specific epigenetic processes (e.g., DNA methyl trans-
ferases, histone deacetylases, etc.).
In addition, as already mentioned briefly, enhancers
appear to be cell-type specific and tissue specific. The
enhancer marks used in this study for neutrophils
and lymphocytes as mapped by the Roadmap Epige-
nomics project were detected in adult blood cells.
There is the possibility that slightly different results
could be obtained from cells in pediatric SLE patients.
Thus, our results may not be generalizable or extrap-
olated, for example, to a pediatric population without
further investigation. Indeed, we already know that
the epigenomes of pathologically relevant cells may
differ from epigenetic marks annotated in Roadmap
data [42]. Coit et al. [40], for example, have shown
that the methylome in CD4+ T cells of patients with
SLE shows distinct differences from what is observed
in healthy controls.
Moreover, the SLE patients included in the GWAS stud-
ies were generated from heterogeneous populations and
most likely included patients with varying clinical manifes-
tations. It is well known that SLE can affect different
organ systems in the body with varying severity, and that
treatment of these manifestations varies from milder im-
munosuppression with hydroxychloroquine alone to more
aggressive immunosuppression with anti-neoplastic agents
for disease control. Recently, Haddon et al. [43] demon-
strated that pediatric SLE patients with kidney
involvement possessed a different autoantibody profile
than those without kidney involvement. Other groups
then showed differences in expression levels of RNA and
microRNAs in lupus nephritis biopsies [44, 45], suggesting
that different clinical phenotypes may have individualized
gene expression signatures.
Table 2 Histone marks in the SNP linkage disequilibrium blocks in CD4+ T cells (Continued)
rs7726414 5 133232663–13877357 309 809 318 Yes
rs7941765 11 128499000–128500215 8 9 2 Yes
rs849142 7 28162674–28200097 1 25 2 Yes
rs9462027 6 34563164–34828553 68 110 66 Yes
rs9652601 16 11164567–11207894 9 78 0 Yes
rs9782955 1 235907825–236041129 22 33 24 Yes
Linkage disequilibrium blocks were obtained from the 1000 Genomes Project pilot 1 and/or HapMap3 database
Chr chromosome, GWAS genome wide association studies, SNP single nucleotide polymorphism
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rs10028805 4 102736456–102762581 44 61 13 Yes
rs10036748 5 150457485–150461049 15 25 14 Yes
rs10488631 7 128585616–128711874 43 62 11 Yes
rs1059312 12 129277164–129288534 33 66 1 Yes
rs10774625 12 111884608–112007756 0 34 0 Yes
rs10807150 6 35154315–35278796 71 110 33 Yes
rs10936599 3 169477506–169528523 32 18 33 Yes
rs11644034 16 85967285–85980534 49 106 23 Yes
rs11889341 2 191943742–191970120 0 0 0 No
rs12022418 1 192521591–192535107 0 0 0 No
rs1270942 6 31704294–32175415 57 58 123 Yes
rs12802200 11 566936–567627 0 0 0 No
rs1610555 18 67523453–67544046 0 0 0 No
rs1801274 1 161470042–161479745 0 8 0 Yes
rs1885889 13 100084234–100104106 17 43 3 Yes
rs2009453 11 65399528–65405300 0 12 0 Yes
rs223881 16 57386566–57317134 0 30 0 Yes
rs2286672 17 4706123–4712617 1 7 7 Yes
rs2289583 15 75285114–75370012 23 122 8 Yes
rs2305772 19 52021247–52034940 2 35 11 Yes
rs2421184 5 158884119–158886939 0 18 0 Yes
rs2431697 5 159879978–159883217 0 2 0 Yes
rs2476601 1 114303808–114377568 18 32 13 Yes
rs2663052 10 50045456–50081232 0 1 0 Yes
rs2732549 11 35073852–35098193 6 47 0 Yes
rs2736340 8 11337587–11353000 40 71 29 Yes
rs2941509 17 37885383–38077485 235 468 84 Yes
rs3024505 1 206939904–206943968 0 48 0 Yes
rs34572943 16 31272353–31276811 0 36 0 Yes
rs3768792 2 213871709–213890232 0 10 0 Yes
rs3794060 11 71138710–71203790 10 28 22 Yes
rs4917014 7 50278187–50308811 17 57 0 Yes
rs4948496 10 63803472–63819903 80 101 17 Yes
rs61616683 22 39747050–39756650 5 17 0 Yes
rs6568431 6 106574794–106597639 4 14 0 Yes
rs6740462 2 65654364–65667272 1 20 27 Yes
rs6932056 6 138132123–138243700 57 115 20 Yes
rs740840 12 6327008–63600683 0 26 0 Yes
rs7444 22 21920817–21983260 14 88 10 Yes
rs7556469 1 198607998–198637582 47 81 26 Yes
rs7726414 5 133232663–13877357 540 1176 284 Yes
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Our results also have implications for the
optimization of therapy in patients with SLE. Jiang
et al. [20] demonstrated that response to treatment in
JIA suggests that children on treatment for JIA can ex-
perience a long period of asymptomatic disease remis-
sion, but continue to have immune cell dysregulation.
Our current treatments for SLE do not “normalize”
immune cell function, as evidenced by continued
periods of disease remission and flare. A better under-
standing of how epigenetic signatures drive gene
expression signatures in SLE patients will allow us to
better determine which patients with which SLE pheno-
types will respond best to different treatments given
their epigenetic profiles.
Table 3 Histone marks in the SNP linkage disequilibrium blocks in CD19+ B cells (Continued)
rs7941765 11 128499000–128500215 19 45 0 Yes
rs849142 7 28162674–28200097 45 120 0 Yes
rs9462027 6 34563164–34828553 95 171 41 Yes
rs9652601 16 11164567–11207894 31 82 0 Yes
rs9782955 1 235907825–236041129 38 71 15 Yes
Linkage disequilibrium blocks were obtained from the 1000 Genomes Project pilot 1 and/or HapMap3 database
Chr chromosome, GWAS genome-wide association studies, SNP single nucleotide polymorphism
Fig. 2 Representative screenshots of functional elements within CD19+ cell genomes generated from the University of California, Santa Cruz
genome browser. Red boxes Potential active enhancers, showing signal peak regions in H3K4me1, H3K4me3, and/or H3K27ac. Upper panel LD
block of SNP rs10028805. Genes within this block are noted. The LD block contains enhancer regions with multiple potential TFBSs (gray and/or
black bars under the TF ChIP-seq track). Lower panel LD block of SNP rs2941509. Similar findings as in Fig. 1a are noted. ChIP data on the
H3K4me1, H3K4me3, and H3K27ac enhancers are from the Roadmap Epigenomics project. ChIP-seq chromatin immunoprecipitation sequencing,
Chr chromosome, hg19 human genome 19, ENCODE Encyclopedia of Functional DNA Elements
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Conclusion
In this study, we have shown that disease-associated
SNPs in SLE lie within LD blocks rich in functional ele-
ments regulating and coordinating gene transcription.
These findings provide new insight into possible links
between genetic and epigenetic risk factors for SLE.
Additional file
Additional file 1: Table S1. is presenting genes (a) and functional
pathways (b), as identified through Panther, associated with SNPs in






























































































































































































































































































































































































































Fig. 3 Enrichment of TFBSs in enhancer regions. a Heatmap of TFBSs in H3K27ac, H3K4me1, and H3K4me3 peak regions in promoter and distal
regions in CD19+ cells. b Heatmap of TFBS in H3K27ac, H3K4me1, and H3K4me3 peak regions in promoter and distal regions in CD4+ cells. c
Heatmap of TFBSs in H3K27ac and H3K4me1 peak regions in promoter and distal regions in neutrophils. Normalized rank: > 0 enrichment (red);
<0 depletion (blue). TF transcription factor (Color figure online)
Hui-Yuen et al. Arthritis Research & Therapy  (2016) 18:281 Page 10 of 12
Abbreviations
ChIP: Chromatin immunoprecipitation; ChIP-seq: Chromatin
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